Scholarlink

Background <p>The accumulation of iron in brain regions is one of the characteristics of Parkinson’s disease (PD). Deferiprone (DFP) is an iron chelator that reduces iron overaccumulation in certain diseases. The efficacy and safety of DFP in the management of PD have been assessed; however, the results remain controversial.</p> Method <p>A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. A comprehensive search was conducted across five databases to identify all randomized clinical trials and observational studies. The primary outcomes included changes in motor function (MDS-UPDRS III) and overall disease severity (MDS-UPDRS total score). Additionally, the safety of DFP was assessed by analyzing adverse events. A network meta-analysis using a random-effects model was conducted.</p> Results <p>Four randomized clinical trials were identified. The studies included 567 patients with early–stage PD. The DFP doses across the included studies ranged from 3.75 to 15&#xa0;mg/kg twice daily. None of the doses showed a significant Improvement in motor function (I2 = 0%), or in overall disease severity (I2 = 82.5%), compared with placebo in the network analysis. However, a non-significant improvement in motor function was observed at 7.5&#xa0;mg/kg twice daily, whereas higher doses were associated with worsening clinical scores. Adverse events were generally mild, although there were some safety concerns at higher doses.</p> Conclusion <p>DFP can reduce accumulated iron across brain regions. However, current evidence does not support the use of DFP for the clinical and symptomatic management of PD within the assessed range of doses and treatment periods.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of deferiprone for Parkinson’s disease: a systematic review and meta-analysis of motor function and overall disease severity

  • 期刊论文

  • 发表日期：

    2026年3月10日

查看全文
  • Ismail A. Ibrahim,
  • Mandy Elewa,
  • Israa A. Solah,
  • Moaz Ezz-Alarab,
  • Rawan Gameel Hekal,
  • Menna Ehab,
  • Amro K. AlQurm,
  • Rahma M. Almetwaly,
  • Ayham R. A. Zidat

摘要

Background

The accumulation of iron in brain regions is one of the characteristics of Parkinson’s disease (PD). Deferiprone (DFP) is an iron chelator that reduces iron overaccumulation in certain diseases. The efficacy and safety of DFP in the management of PD have been assessed; however, the results remain controversial.

Method

A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. A comprehensive search was conducted across five databases to identify all randomized clinical trials and observational studies. The primary outcomes included changes in motor function (MDS-UPDRS III) and overall disease severity (MDS-UPDRS total score). Additionally, the safety of DFP was assessed by analyzing adverse events. A network meta-analysis using a random-effects model was conducted.

Results

Four randomized clinical trials were identified. The studies included 567 patients with early–stage PD. The DFP doses across the included studies ranged from 3.75 to 15 mg/kg twice daily. None of the doses showed a significant Improvement in motor function (I2 = 0%), or in overall disease severity (I2 = 82.5%), compared with placebo in the network analysis. However, a non-significant improvement in motor function was observed at 7.5 mg/kg twice daily, whereas higher doses were associated with worsening clinical scores. Adverse events were generally mild, although there were some safety concerns at higher doses.

Conclusion

DFP can reduce accumulated iron across brain regions. However, current evidence does not support the use of DFP for the clinical and symptomatic management of PD within the assessed range of doses and treatment periods.